Metabolic
Mazdutide
Also called IBI362, LY3305677
per administration
A human trial worked out how much to take and how often, so a dosing schedule is shown.
Licensed as a medicine in China.
Quick start
Mazdutide at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.
- Typical dose
- 3–9 mg per administration
- How often
- Once a week
- Where
- Subcutaneous — abdomen, thigh, or upper arm Sites and rotation
- Time to steady level
- ~25.0 days — about five half-lives
- Storage
- Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
Work out your draw
These numbers are a starting point — change any of them.
Vial label
Copy this into your label printer.
Published research contexts for Mazdutide describe 3–9 mg per administration. Descriptive only, not a recommendation.
Multi-day elimination consistent with once-weekly dosing; a precise human half-life is not well characterised in accessible literature.
A GLP-1/glucagon dual receptor agonist authorized in China. Exact maintenance amounts vary across the trial program — 4 and 6 mg once weekly in the phase-3 weight study and up to 9 mg in later dose-finding — so the steps below are a conservative reading, not a single fixed schedule.
Dosing schedule
How Mazdutide is commonly stepped up, for reference only.
These are commonly-discussed research protocols shared for educational reference. This is not medical advice and is not a substitute for guidance from a qualified professional.
| Phase | Amount | Frequency | Route |
|---|---|---|---|
| Weeks 1–4Reported starting step; step up every 4 weeks as tolerated. | 3 mg | Once weekly | SubQ |
| Weeks 5–8 | 4.5 mg | Once weekly | SubQ |
| Week 9+Approved maintenance step; 9 mg was studied in later work for a larger reduction. | 6 mg | Once weekly | SubQ |
Modelled level — once a week
1× is the peak after a single dose.
- Steady-state peak
- 1.57× single dose
- Time to steady state
- 25.0days
- Administrations
- 1/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- GLORY-1 phase-3 trial (Innovent; NEJM 2025)Once-weekly mazdutide 4 and 6 mg over 48 weeks in Chinese adults with overweight or obesity; authorized in China for weight management in 2025.